-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple sclerosis (MS) is a triggered by environmental factors own immune disease, which acts on genetically susceptible host
.
One of the least-known aspects of multiple sclerosis is the biological factors associated with the transition from relapsing-remitting multiple sclerosis (RRMS) to progressive multiple sclerosis
Immunity Therefore, there is an urgent need to understand the factors associated with progressive multiple sclerosis and how to change these factors
antibiotic
In addition, bacteria may induce spinal cord inflammation through the combined effects of biological simulation and inflammation
.
Colonization of spontaneous EAE mice with microbiota from RRMS patients can worsen the disease and is associated with a decrease in IL-10 producing T regs
, Indicating that the MS microbiota lacks both beneficial microorganisms that regulate self-immunity, and has too many pro-inflammatory bacteria
Studies have found that patients with RRMS have lower levels of Prevotella, and administration of human-derived Prevotella can improve EAE, indicating that increasing the consumption of bacteria can reduce neuroinflammation
.
Administration of probiotics to patients with RRMS can reverse the inflammatory phenotype of peripheral monocytes, and the immune changes remain persistent after a few months of stopping the use of probiotics
In this way, Laura M.
Cox and others of Harvard University explored the gut microbiome of advanced multiple sclerosis (MS) and its relationship with clinical diseases
They found that the β-diversity of the microbiota differed between patients with multiple sclerosis and the control group, but there was no difference between RRMS and progressive MS, and there was no difference based on disease-modifying therapies
.
Disease status has the greatest impact on the β-diversity of the microbiota, followed by body mass index, race, and gender
.
In progressive multiple sclerosis and RRMS, Clostridium Bolteae, Ruthenibacterium lactatiformans and Akkermansia increased, and Blautia wexlerae, Dorea formicigenerans and Erysipelotrichaceae CCMM decreased
.
Some Clostridia are associated with higher EDSS and fatigue scores
In addition, Akkermansia isolated from MS patients can improve EAE, which is related to the reduction of RORγt+ and γδ T cells that produce IL-17
.
.
In addition, Akkermansia isolated from MS patients can improve EAE, which is related to the reduction of RORγt+ and γδ T cells that produce IL-17
.
The important significance of this study is that although some microbiota changes are common in relapsing and progressive multiple sclerosis, unique bacteria related to the clinical measures of progressive multiple sclerosis and disease have been discovered
.
In addition, the increase in Axmansia in multiple sclerosis may be a compensatory beneficial response in the multiple sclerosis microbiota
.
Original source:
Cox LM, Maghzi AH, Liu S, Tankou SK, Dhang FH, Willocq V, Song A, Wasén C, Tauhid S, Chu R, Anderson MC, De Jager PL, Polgar-Turcsanyi M, Healy BC, Glanz BI , Bakshi R, Chitnis T, Weiner HL.
Gut Microbiome in Progressive Multiple Sclerosis.
Ann Neurol.
2021 Jun;89(6):1195-1211.
doi: 10.
1002/ana.
26084.
Epub 2021 Apr 30.
PMID: 33876477; PMCID : PMC8132291.
Leave a message here